Sarcoma  >>  Proleukin (aldesleukin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
NCT00003408: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Completed
2
40
US
aldesleukin, recombinant interferon alfa, sargramostim
Cancer Treatment Centers of America
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
 
03/00
NCT02259348: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated
2
12
US
Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Fludarabine monophosphate, G-CSF, Filgrastim, Neupogen®, Interleukin-2, IL-2, Aldesleukin, Melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran®, Thiotepa, ThioplexV, TESPA, TSPA, Rituximab, Rituxan™, Natural killer cell therapy, NK cell therapy, T-cell depleted HPC transplant, HPC,A Infusion(ɑ/β T cell depleted), CD45RA-depleted HPC transplant
St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
04/15
03/16
NCI-2018-00918, NCT03449108: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting
2
30
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous TILs LN-145, Autologous Tumor-infiltrating Lymphocytes LN-145, LN-145, LN145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous TILs LN-145-S1, Autologous Tumor-infiltrating Lymphocytes LN-145-S1, LN 145-S1, LN-145-S1, LN145-S1, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, Iovance Biotherapeutics, Inc., National Cancer Institute (NCI)
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
06/25
06/25
2016-003578-42: Infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas. Infusión de células NK activadas para el tratamiento de niños, adolescentes y adultos jóvenes con sarcomas.

Ongoing
1/2
10
Europe
NK cells, Proleukin, Injection, Powder for solution for injection/infusion, PROLEUKIN
Antonio Pérez-Martínez, Servicio de Hemato-Oncología Infantil. Hospital Universitario La Paz.
Sarcoma Sarcoma, Sarcoma Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01454596: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Hourglass Jan 2016 - Dec 2016 : For glioblastoma
Completed
1/2
18
US
Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Proleukin, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
11/18
01/19
NCT02173093: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Unknown status
1/2
40
US
IL-2, aldesleukin, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, GD2Bi-aATC, GD2Bi-armed aATC, GM-CSF, sargramostin, Leukine, Prokine, laboratory evaluations of immune responses, laboratory biomarker analysis
University of Virginia, National Cancer Institute (NCI)
Disseminated Neuroblastoma, Recurrent Neuroblastoma
12/19
12/19
NCT05296564: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Recruiting
1/2
3
RoW
CYCLOPHOSPHAMIDE and FLUDARABIN, CYTOXAN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin, Interleukin-2
Hadassah Medical Organization
Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Bladder Urothelial Carcinoma, Neuroblastoma, Metastatic, Ovary Cancer
12/27
12/27

Download Options